Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis

CJ. Stavast, I. van Zuijen, E. Karkoulia, A. Özçelik, A. van Hoven-Beijen, LG. Leon, JSA. Voerman, GMC. Janssen, PA. van Veelen, M. Burocziova, RWW. Brouwer, WFJ. van IJcken, A. Maas, EM. Bindels, VHJ. van der Velden, C. Schliehe, PD. Katsikis,...

. 2022 ; 36 (3) : 687-700. [pub] 20211105

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010891
E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 34741119
DOI 10.1038/s41375-021-01461-5
Knihovny.cz E-zdroje

MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139 and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show that MLL-AF9 expression in hematopoietic precursors caused epigenetic silencing of MIR139, whereas overexpression of MIR139 inhibited in vitro and in vivo AML outgrowth. We identified novel miR-139 targets that mediate the tumor-suppressing activities of miR-139 in MLL-AF9 AML. We revealed that two enhancer regions control MIR139 expression and found that the polycomb repressive complex 2 (PRC2) downstream of MLL-AF9 epigenetically silenced MIR139 in AML. Finally, a genome-wide CRISPR-Cas9 knockout screen revealed RNA Polymerase 2 Subunit M (POLR2M) as a novel MIR139-regulatory factor. Our findings elucidate the molecular control of tumor suppressor MIR139 and reveal a role for POLR2M in the MIR139-silencing mechanism, downstream of MLL-AF9 and PRC2 in AML. In addition, we confirmed these findings in human AML cell lines with different oncogenic aberrations, suggesting that this is a more common oncogenic mechanism in AML. Our results may pave the way for new targeted therapy in AML.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010891
003      
CZ-PrNML
005      
20220506130104.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-021-01461-5 $2 doi
035    __
$a (PubMed)34741119
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Stavast, Christiaan J $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands $1 https://orcid.org/0000000314603112
245    14
$a The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis / $c CJ. Stavast, I. van Zuijen, E. Karkoulia, A. Özçelik, A. van Hoven-Beijen, LG. Leon, JSA. Voerman, GMC. Janssen, PA. van Veelen, M. Burocziova, RWW. Brouwer, WFJ. van IJcken, A. Maas, EM. Bindels, VHJ. van der Velden, C. Schliehe, PD. Katsikis, M. Alberich-Jorda, SJ. Erkeland
520    9_
$a MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139 and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show that MLL-AF9 expression in hematopoietic precursors caused epigenetic silencing of MIR139, whereas overexpression of MIR139 inhibited in vitro and in vivo AML outgrowth. We identified novel miR-139 targets that mediate the tumor-suppressing activities of miR-139 in MLL-AF9 AML. We revealed that two enhancer regions control MIR139 expression and found that the polycomb repressive complex 2 (PRC2) downstream of MLL-AF9 epigenetically silenced MIR139 in AML. Finally, a genome-wide CRISPR-Cas9 knockout screen revealed RNA Polymerase 2 Subunit M (POLR2M) as a novel MIR139-regulatory factor. Our findings elucidate the molecular control of tumor suppressor MIR139 and reveal a role for POLR2M in the MIR139-silencing mechanism, downstream of MLL-AF9 and PRC2 in AML. In addition, we confirmed these findings in human AML cell lines with different oncogenic aberrations, suggesting that this is a more common oncogenic mechanism in AML. Our results may pave the way for new targeted therapy in AML.
650    _2
$a zvířata $7 D000818
650    _2
$a karcinogeneze $x genetika $7 D063646
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x genetika $7 D015470
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a protoonkogenní protein MLL $x genetika $7 D051788
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a RNA-polymerasa II $x genetika $7 D012319
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van Zuijen, Iris $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
700    1_
$a Karkoulia, Elena $u Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $u Childhood Leukemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Özçelik, Arman $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
700    1_
$a van Hoven-Beijen, Antoinette $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
700    1_
$a Leon, Leticia G $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
700    1_
$a Voerman, Jane S A $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
700    1_
$a Janssen, George M C $u Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a van Veelen, Peter A $u Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a Burocziova, Monika $u Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Brouwer, Rutger W W $u Erasmus MC, University Medical Center Rotterdam, Center for Biomics, Rotterdam, the Netherlands $u Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands
700    1_
$a van IJcken, Wilfred F J $u Erasmus MC, University Medical Center Rotterdam, Center for Biomics, Rotterdam, the Netherlands $u Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands $1 https://orcid.org/0000000204218301
700    1_
$a Maas, Alex $u Erasmus MC, University Medical Center Rotterdam, Department of Cell Biology, Rotterdam, the Netherlands
700    1_
$a Bindels, Eric M $u Erasmus MC, University Medical Center Rotterdam, Department of Hematology, Rotterdam, the Netherlands
700    1_
$a van der Velden, Vincent H J $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands $1 https://orcid.org/0000000194573763
700    1_
$a Schliehe, Christopher $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands
700    1_
$a Katsikis, Peter D $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands $1 https://orcid.org/0000000176905218
700    1_
$a Alberich-Jorda, Meritxell $u Department of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $u Childhood Leukemia Investigation Prague, Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Erkeland, Stefan J $u Erasmus MC, University Medical Center Rotterdam, Department of Immunology, Rotterdam, the Netherlands. s.erkeland@erasmusmc.nl $1 https://orcid.org/0000000210197957
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 36, č. 3 (2022), s. 687-700
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34741119 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130057 $b ABA008
999    __
$a ok $b bmc $g 1788825 $s 1162089
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 3 $d 687-700 $e 20211105 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace